Health‑and‑wellness company LifeVantage Corporation announced that an independent in‑vitro study of its proprietary P84 formula observed marked changes in the production of 14 gut peptides and proteins associated with gut regulation, repair and restoration. The study measured results across four gut cell types and reported significant increases in key molecules: gastrin‑releasing peptide (GRP) rose around +1,087 %; trefoil factor 3 (TFF3) increased approx. +116 %; vasoactive intestinal peptide (VIP) increased +100 %; oxyntomodulin (OXM) +77 %; and cholecystokinin (CCK) +69 %.
LifeVantage said the results “exceeded typical biomarker thresholds” — noting that biomarker changes of 20‑30 % are often considered biologically meaningful in cell models, and that P84 produced higher percentage changes across multiple targets. The company also described next research steps, including mRNA sequencing of P84 in combination with its other products (Protandim® Nrf2 Synergizer® and MindBody GLP‑1 System™) to further understand mechanistic pathways.
Additionally, LifeVantage noted that P84 was brought into its product portfolio through its October 2025 acquisition of the assets of LoveBiome, a company focused on microbiome and gut health solutions. The firm said P84 is intended as part of its wider “Activators” line targeting cellular and microbiome wellness.
It is important to note that the findings are in‑vitro only (laboratory cell models) and do not provide evidence of clinical benefit in humans. The company acknowledged that while these mechanistic results are promising, further study will be required to establish real‑world health impact for consumers.
